An interventional study of Retrograde Intrarenal Surgery and Mini Percutaneous Nephrolithotomy in Kidney Stones and Nephrolithiasis, sponsored by Necmettin Erbakan University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Necmettin Erbakan University · Not applicable, Interventional, and Treatment
This prospective cohort study aims to compare the safety and efficacy of retrograde intrarenal surgery combined with a high-power Holmium:YAG laser and flexible navigable suction access sheath versus mini-percutaneous nephrolithotomy in patients with 2-3 cm renal stones.
597 studies on the registry are indexed under Kidney Calculi; 162 are open to participants now.
This study's enrollment of 60 is below the median of 90 across 460 interventional studies indexed under Kidney Calculi.
Browse Kidney Calculi studies →Necmettin Erbakan University is the lead sponsor of 198 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intervention: Procedure-Retrograde Intrarenal Surgery
Procedure: Retrograde Intrarenal Surgery
Intervention: Procedure- Mini Percutaneous Nephrolithotomy
Procedure: Mini Percutaneous Nephrolithotomy
We performed retrograde intrarenal surgery combined with a high-power Holmium:YAG laser and flexible navigable suction access sheath in patients with 2-3 cm renal stones.
We performed mini-percutaneous nephrolithotomy in patients with 2-3 cm renal stones.
Stone-Free Rate
Time frame: 1 month
Hemoglobin change
Time frame: postoperative first day
Fluoroscopy time
Time frame: Perioperative
Complications
Time frame: up to 4 weeks
Plan to share: Yes
Supporting information: Study protocol
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Necmettin Erbakan University